{"name":"Yung-Jue Bang","slug":"yung-jue-bang","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBna0tvTzIxejd1WDIyTFBSYTNGM0V2UC1zZi00TkhYaXFIV0d2SG1ad1RXendtMFpacnhKYmxGYU5KQzcxeWQ0RnI0ZEc4emdMdDE5RWdmcVFEUmN3N3pn?oc=5","date":"2024-05-14","type":"trial","source":"Nature","summary":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial - Nature","headline":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5Ta0MtVEpwdHg4ZjFWUG5rZHZTN0FpcU1WWjdhczhva09jWWF5RlpmWVRFWXZXWTVnZGdrd2NOcWw0djBRdE1kNXFRSDlDamVvWEROUVdIclZmdEd6a3lKRmEyaGtEc3F4OG5pUFNR0gFyQVVfeXFMT2tLcktWTWJ4VVpVbXJWTUh4Q1ZRcnBfUEo4WUFwQWI4S25kUjBhLWNOcWFsV0hyNEJCMDlMRHJEN1BoRFdtRTZtLWVsVnAtWG9tMWJqaER5Z2JSLVRYbTh5aVAzZkJCWXJlR3lrTUo1amFR?oc=5","date":"2023-11-20","type":"pipeline","source":"koreabiomed.com","summary":"10 Korean physicians in top 1% of influential researchers in clinical medicine - koreabiomed.com","headline":"10 Korean physicians in top 1% of influential researchers in clinical medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBfc0I0NDNGVDRJM3ZxMlhnMDhIdTJzdzRwNGtsQ0w3X3JLQW5yaVFVX0M0Zi1xcF9YR2JmdXBwblV0Z2hWRk1VRWpwNTN5STFYS2tZUG5oWUVJUGJRZ0Rz?oc=5","date":"2023-07-31","type":"trial","source":"Nature","summary":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial - Nature","headline":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOQUpyTGduVWt3QkE4c2hiZGtCeDZJN3JSM2JKazFHU3ZreHBORm1KMjRVOUNpY2JXRDYxRUZzQm53Ukd5dE5mNGpTOXhxQ1lUZmR3bk45bUh0bnVkOEJfNzRtQl9BSFZwUXlYM2N4di1UaU9QbFhwZDJfbG1XYS1CT0hMQW9pRFc5YldR?oc=5","date":"2023-04-24","type":"trial","source":"The Lancet","summary":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): ","headline":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable o","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBzRVNTTWZQaWFCOEJ2dVVNekdLZ2hzZmUzVlJ6MGN4T1Q4bWpidHZyY01QcVBGWFhjdHJfNkdGU29nOFJCV0F4NW5CQmpUbmJuTUs2eXBNN25yQzJQV1hvVmFQelhMSE5LRGhtcU1R0gFyQVVfeXFMUF93NmpEWWVEU2RTZnVqSlZ1Rk5rU01NaWN1VGZOb1d5bk5DYWIxYld2NFF1UVBwSEJzSzI0OXRSbUFfSE1wa0pFR18yeHZNVlUtNGNWWHdITnZtTGRuc05Ta1lkTnNzZlRMdnNJOEVjVzZR?oc=5","date":"2022-11-17","type":"pipeline","source":"koreabiomed.com","summary":"Who are Korean doctors named in the ‘World's Top 1% Researchers’? - koreabiomed.com","headline":"Who are Korean doctors named in the ‘World's Top 1% Researchers’?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQNTV1MUxHbGF3M2NqbXZqYWNldGh0cWhWcHFDc1ZsOFFnN2ZoR0tuR09TSmsxV2xVTHgxd0R6aXBBTk83RzVoU2pURkNoSzVFby12amhsenpiVzVndHdGYkRnQVA2SjNMSU9JQUM0Y01CWUlKbWhwb3M2RjdUU2tpMjlSc2NONjUxMmM2TWE2czVlVW9uUURJ?oc=5","date":"2019-02-15","type":"pipeline","source":"Asian Scientist Magazine","summary":"Asia’s Scientific Trailblazers: Bang Yung-Jue - Asian Scientist Magazine","headline":"Asia’s Scientific Trailblazers: Bang Yung-Jue","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE43WU9sS1d4ODNJbHhyeklNT0otbVo2V29iaG1BeVZ0MU5CN1NYVGNHbjNIcm0xamRBenB1ODIyNGhORzlRdzVCU29EblEwenV5eGhjZVFud2xtcDFoY2MzMA?oc=5","date":"2011-02-10","type":"pipeline","source":"NEJM","summary":"Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors - NEJM","headline":"Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBicTZJQ1MxeDlIeW9qWGZOMkpFRkVoMmE2aEFqRXhxb0R6UjBsUzJBZkdZSm5iMXJoRnZFc1RmQjdFYVF6NFVaRXhRbjEwd2pEOTRaR2NfRmVxVEpCb0pz?oc=5","date":"2010-10-28","type":"pipeline","source":"NEJM","summary":"Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer - NEJM","headline":"Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBVdU9XcnNZbDJ1aXV3NUEtOC1NOVVuY1F3T2ZrQTEwd20wcjlrcklpMUtJdzdDQW1Cc0lTSFBMRU12QjRVRVlxWWxSc21YamViMmNDcmJ1SGk2clRBNW9ub19HcElDb0pqNWZmNzgwSUNTNmd6ZHhUSFFUb1I?oc=5","date":"2010-06-07","type":"pipeline","source":"Hartford Business Journal","summary":"Pfizer’s lung cancer drug promising - Hartford Business Journal","headline":"Pfizer’s lung cancer drug promising","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}